Archive

HIGHLIGHTS

 
BioCentury: LSP's Four of a Kind
To read the full article click here
 
LSP leads € 15M series A round of Cardiovascular start-up Cardior Pharmaceuticals
Munich, Germany — May 11, 2017 — LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series A Round of Cardior Pharmaceuticals, a private German company develo[...]
 
LSP Portfolio Company Luxendo acquired by Bruker
Successful exit after 1,5 years validates LSPs investment rationale   Munich, Germany ─ May 8, 2017 ─ LSP today announced that it has sold its portfolio company Luxendo, a spin-off of the European Molecul[...]
 
LSP extends its portfolio in immuno-oncology and invests in the € 20 million Series A round of Imcheck Therapeutics
Amsterdam, the Netherlands — May 3, 2017 — LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series A Round of Imcheck Therapeutics, a private French company[...]
 
Marco Groot blikt in het FD terug op zijn eerdere positieve aanbeveling op LSP
Lees de gehele column: Actief beleggen loont
 
LSP’s portfolio company Neuravi acquired by Codman Neuro
Amsterdam, the Netherlands, April 10, 2017 – LSP (Life Sciences Partners), a leading European investor in health care, announces the acquisition of its portfolio company Neuravi Limited by Codman Neuro, part of the [...]
 
LSP’s portfolio company argenx raises approximately $100 million with NASDAQ IPO
Amsterdam, The Netherlands – 19 May 2017 – It is with great pleasure that LSP – the specialist European healthcare investment firm – announces that its portfolio company argenx (Euronext Brussels: ARGX) was su[...]
 
LSP Venture Partner Hans Clevers gets prestigious Körber Award for his ground breaking research into stem cells and organoids, and appears in Germ...
To see the video click here    
 
LSP announces $280 million final closing of life sciences venture fund
Amsterdam, 2nd June 2016 - LSP (Life Sciences Partners), the European life sciences investment group, today announced the final closing of its new life sciences fund, LSP 5. The fund surpassed its $170 million target [...]
 
LSP and Bristol-Myers Squibb enter into strategic collaboration for life sciences innovation in Europe
First investment by Bristol-Myers Squibb in a European healthcare fund      Munich and New York, 24 November, 2015—LSP (Life Sciences Partners), the specialist healthcare investment firm, has announced to[...]
 
LSP COMPANY NEWS
LSP’s portfolio company Merus announces deal with Incyte
 
Marco Groot over LSP in het FD
Lees de gehele column: Een absoluut beter resultaat

2017


LSP portfolio company Imcheck Therapeutics obtains 1M€ from Bpifrance to contribute to the development of a novel therapeutic antibody in immuno-oncology
First non-dilutive funding received by ImCheck  following its initial fundraising of 20 M€ in May 2017   Marseille, France, 10 October 2017 – ImCheck Therapeutics, an emerging biopharmaceutical compa [...]
argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis
Non-regulated information   Breda, the Netherlands / Ghent, Belgium, September 25, 2017 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated [...]
argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia
Top-line data from the study expected in second half of 2018  -    Breda, the Netherlands / Ghent, Belgium, September 20, 2017 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company [...]
Kiadis Pharma receives FDA Regenerative Medicine Advanced Therapy (RMAT) designation for ATIR101™
Amsterdam-Duivendrecht, The Netherlands, September 20, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developi [...]
Merus’ Intellectual Property Portfolio Expands with Two New Patents For its Biclonics® Technology
UTRECHT, The Netherlands, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Merus (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing therapeutics with the goal of treating and curing serious illnesses, announced toda [...]
Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress
UTRECHT, The Netherlands, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced fin [...]


2017
2016
2015
2014
2013
2012
back to news overview

Archive

HIGHLIGHTS

 
BioCentury: LSP's Four of a Kind
To read the full article click here
 
LSP leads € 15M series A round of Cardiovascular start-up Cardior Pharmaceuticals
Munich, Germany — May 11, 2017 — LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series A Round of Cardior Pharmaceuticals, a private German company develo[...]
 
LSP Portfolio Company Luxendo acquired by Bruker
Successful exit after 1,5 years validates LSPs investment rationale   Munich, Germany ─ May 8, 2017 ─ LSP today announced that it has sold its portfolio company Luxendo, a spin-off of the European Molecul[...]
 
LSP extends its portfolio in immuno-oncology and invests in the € 20 million Series A round of Imcheck Therapeutics
Amsterdam, the Netherlands — May 3, 2017 — LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series A Round of Imcheck Therapeutics, a private French company[...]
 
Marco Groot blikt in het FD terug op zijn eerdere positieve aanbeveling op LSP
Lees de gehele column: Actief beleggen loont
 
LSP’s portfolio company Neuravi acquired by Codman Neuro
Amsterdam, the Netherlands, April 10, 2017 – LSP (Life Sciences Partners), a leading European investor in health care, announces the acquisition of its portfolio company Neuravi Limited by Codman Neuro, part of the [...]
 
LSP’s portfolio company argenx raises approximately $100 million with NASDAQ IPO
Amsterdam, The Netherlands – 19 May 2017 – It is with great pleasure that LSP – the specialist European healthcare investment firm – announces that its portfolio company argenx (Euronext Brussels: ARGX) was su[...]
 
LSP Venture Partner Hans Clevers gets prestigious “Körber Award” for his ground breaking research into stem cells and organoids, and appears in Germ...
To see the video click here    
 
LSP announces $280 million final closing of life sciences venture fund
Amsterdam, 2nd June 2016 - LSP (Life Sciences Partners), the European life sciences investment group, today announced the final closing of its new life sciences fund, LSP 5. The fund surpassed its $170 million target [...]
 
LSP and Bristol-Myers Squibb enter into strategic collaboration for life sciences innovation in Europe
First investment by Bristol-Myers Squibb in a European healthcare fund      Munich and New York, 24 November, 2015—LSP (Life Sciences Partners), the specialist healthcare investment firm, has announced to[...]
 
LSP COMPANY NEWS
LSP’s portfolio company Merus announces deal with Incyte
 
Marco Groot over LSP in het FD
Lees de gehele column: Een absoluut beter resultaat

$smarty.now|date_format:"%Y"


LSP portfolio company Imcheck Therapeutics obtains 1M€ from Bpifrance to contribute to the development of a novel therapeutic antibody in immuno-oncolo...
First non-dilutive funding received by ImCheck  following its initial fundraising of 20 M€ in May 2017   Marseille, France, 10 October 2017 – ImCheck Therapeutics, an emerging biopharmaceutical compa [...]
argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis
Non-regulated information   Breda, the Netherlands / Ghent, Belgium, September 25, 2017 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated [...]
argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia
Top-line data from the study expected in second half of 2018  -    Breda, the Netherlands / Ghent, Belgium, September 20, 2017 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company [...]
Kiadis Pharma receives FDA Regenerative Medicine Advanced Therapy (RMAT) designation for ATIR101™
Amsterdam-Duivendrecht, The Netherlands, September 20, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developi [...]
Merus’ Intellectual Property Portfolio Expands with Two New Patents For its Biclonics® Technology
UTRECHT, The Netherlands, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Merus (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing therapeutics with the goal of treating and curing serious illnesses, announced toda [...]
Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress
UTRECHT, The Netherlands, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced fin [...]


2017
2016
2015
2014
2013
2012
back to news overview